<table>
<thead>
<tr>
<th>VACCINE</th>
<th>TYPE</th>
<th>NAME</th>
<th>STATUS</th>
<th>PHASES</th>
<th>ELA SUBMISSION</th>
<th>FULL FDA APPROVAL</th>
<th>FIRST DOSE</th>
<th>SECOND DOSE</th>
<th>PEDIATRICS</th>
<th>PREVENTION OF SEVERE ILLNESS</th>
<th>DELTA B.1.1.7</th>
<th>Omicron B.1.1.59</th>
<th>ADMINISTRATION</th>
<th>DOSES</th>
<th>TIMING</th>
<th>PRODUCTS</th>
<th>STORAGE PREPARATION</th>
<th>STABILITY INFORMATION</th>
<th>POPULATION</th>
<th>TIMING</th>
</tr>
</thead>
<tbody>
<tr>
<td>mRNA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer-BioNTech (mRNA-1273)</td>
<td>Pfizer-BioNTech (BNT162b2) (Comirnaty)</td>
<td>Phase 2 &amp; 3</td>
<td>(4,000)</td>
<td></td>
<td>ELA approved for ages 5 and above</td>
<td>Ages 16 and above</td>
<td>52%</td>
<td>91%</td>
<td>100%</td>
<td>Ages 12-17, 90.7% Ages 5-11</td>
<td>93%</td>
<td>53% - 55%</td>
<td>VE against Delta hospitalization 95%</td>
<td>Two Doses: 70% against hospitalization Booster: 85%</td>
<td>IM</td>
<td>Click for administration instructions</td>
<td>Adult/Adolescent: Primary: 2 0.34mL/Dose Booster (Age 12+): 1 0.34mL/Dose Pediatric: Primary: 0.20mL/Dose</td>
<td>Pfizer product information</td>
<td>Additional 3rd Full Dose for immunocompromised 1. Active cancer treatment or blood cancer 2. Organ transplant and taking immunosuppressants 3. Stem cell transplant in the last 2 years 4. Moderate/severe immune deficiency 5. Advanced for untreated HIV 6. High dose corticosteroids or other immunosuppressants</td>
<td>Note: Count as primary series</td>
</tr>
<tr>
<td>Moderna Spikevax (mRNA-1273)</td>
<td>Moderna (BNT162b2)</td>
<td>Phase 3</td>
<td>(30,000)</td>
<td></td>
<td>N/A</td>
<td>NEW! Ages 16 and above</td>
<td>80%</td>
<td>93%</td>
<td>100%</td>
<td>primary definition (secondary CDC definition)</td>
<td>95%</td>
<td>95%</td>
<td>66.7% VE against Delta hospitalization 97.6%</td>
<td>Booster increases neutralizing antibody levels approximately 27-fold</td>
<td>IM</td>
<td>Click for administration instructions</td>
<td>Adult/Adolescent: Primary: 2 0.5mL/Dose Booster: 1 0.25mL/Dose</td>
<td>Moderna product information</td>
<td>Click for Moderna product information</td>
<td>All persons aged ≥12 years may receive a single COVID-19 vaccine booster dose 5 months after completion of their primary mRNA vaccine series. Moderna: All persons aged ≥18 years may receive a single COVID-19 vaccine booster dose 5 months after completion of their primary mRNA vaccine series. Janseen: All persons aged ≥18 years may receive a single COVID-19 vaccine booster dose 2 months after completion of their primary mRNA vaccine series.</td>
</tr>
<tr>
<td>Protein Subunit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Novavax (NVX-CoV2373)</td>
<td>Novavax (NVX-CoV2373)</td>
<td>Phase 3</td>
<td>(30,000)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral Vector</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxford/ AstraZeneca (ChAdOx1)</td>
<td>Oxford/ AstraZeneca (ChAdOx1)</td>
<td>Phase 3</td>
<td>(30,000)</td>
<td></td>
<td>Considering bypassing ELA approval and going for BLA approval</td>
<td>Considering bypassing ELA approval and going for BLA approval</td>
<td>79%</td>
<td>94%</td>
<td>Booster date</td>
<td>Safety and efficacy has not been established in individuals younger than 18</td>
<td>74%</td>
<td>91%</td>
<td>VE reduction in effectiveness including against Delta variant</td>
<td>No production of antibodies</td>
<td>IM</td>
<td>Click for administration instructions</td>
<td>Adult/Adolescent: Primary: 1 Booster: 1 (Booster recommended after two months)</td>
<td>Pfizer product information</td>
<td>All persons who are 18 and older who were vaccinated two or more months ago should receive a booster dose (Pfizer-BioNTech, Moderna preferred)</td>
<td>Booster: Pfizer-BioNTech All persons aged ≥12 years may receive a single COVID-19 vaccine booster dose 5 months after completion of their primary mRNA vaccine series. Moderna: All persons aged ≥18 years may receive a single COVID-19 vaccine booster dose 5 months after completion of their primary mRNA vaccine series.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Disclaimer:** The currency of the information, for any errors or omissions, and/or for any rapidly evolving because of ongoing research and events and is subject to the accuracy and appropriateness of the information presented. However, the reader of this document is cautioned that ASHP makes no representation, and reader of this information is advised that ASHP is not responsible for the uniqueness of the needs of individual patients. ASHP provides this information to help practitioners better understand the current status of COVID-19 vaccine informational sheet is emerging information to help practitioners better understand the current status of COVID-19 vaccine planning efforts; a number of resources are available on our COVID-19 Vaccine page. Updated 02/02/2022

**COVID-19 Vaccine Information:**

- **Pfizer-BioNTech:** Approved for adults and adolescents 16+ years and above. Pending approval for ages 5-11 years. Approved for EUA May 12, 2021.
- **Moderna:** Approved for adults and adolescents 16+ years and above. Pending approval for ages 12-15 years. Approved for EUA December 22, 2020.
- **Janssen/J&J:** Approved for adults and adolescents 18+ years and above. Pending approval for ages 12-15 years. Approved for EUA February 27, 2021.
- **AstraZeneca:** Approved for adults 18+ years and above. Pending approval for ages 12+ years. Approved for EUA January 31, 2021.
- **Novavax:** Application submitted to FDA January 31, 2023. Not quantified 90% currently studying in age 12-17 300%.
- **Oxford/AstraZeneca (ChAdOx1):** Considering bypassing ELA approval and going for BLA approval.

**Efficacy:***

- **Pfizer-BioNTech:** 95% efficacy against symptomatic COVID-19. 90.7% efficacy against Delta variant.
- **Moderna:** 94.5% efficacy against COVID-19. 91% efficacy against Delta variant.
- **Janssen/J&J:** 66.1% efficacy against COVID-19. 91% efficacy against Delta variant.
- **AstraZeneca:** 76% efficacy against COVID-19. 93% efficacy against Delta variant.
- **Novavax:** 80% efficacy against COVID-19. Not quantified.

**Additional Dose/Booster for mRNA Vaccines:***

- **Pfizer-BioNTech:** Booster: 85% efficacy against hospitalization. Booster: 85% efficacy against Delta variant.
- **Moderna:** Booster: 87% efficacy against hospitalization. Booster: 74% efficacy against Delta variant.
- **Janssen/J&J:** Booster: 72% efficacy against hospitalization. Booster: 78% efficacy against Delta variant.
- **AstraZeneca:** Booster: 76% efficacy against hospitalization. Booster: 70% efficacy against Delta variant.
- **Novavax:** Booster: 80% efficacy against hospitalization. Booster: 80% efficacy against Delta variant.

**Additional Dose/Booster for Subunit Vaccines:***

- **Pfizer-BioNTech:** Booster: 70% efficacy against hospitalization. Booster: 85% efficacy against Delta variant.
- **Moderna:** Booster: 87% efficacy against hospitalization. Booster: 74% efficacy against Delta variant.
- **Janssen/J&J:** Booster: 72% efficacy against hospitalization. Booster: 78% efficacy against Delta variant.
- **AstraZeneca:** Booster: 76% efficacy against hospitalization. Booster: 70% efficacy against Delta variant.
- **Novavax:** Booster: 80% efficacy against hospitalization. Booster: 80% efficacy against Delta variant.

**ASHP Statement:** ASHP will continue to be active in behalf of our members and support COVID-19 vaccine planning efforts; a number of resources are available on our COVID-19 Vaccine page.